๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetic profiles of current therapiesfor Alzheimer's disease: implications for switching to galantamine

โœ Scribed by Martin R. Farlow

Book ID
117321192
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
756 KB
Volume
23
Category
Article
ISSN
0149-2918

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Patterns of decline and evidence of subg
Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months
โœ Kenneth Rockwood; Dingwei Dai; Arnold Mitnitski ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 107 KB ๐Ÿ‘ 2 views

## Abstract ## Background Lacking longโ€term placeboโ€controlled trials of cholinesterase inhibitors (ChEIs) in Alzheimer's disease, how decline is modeled is crucial to interpreting the effects of longโ€term, openโ€label use. We aimed to: 1) understand changes in cognition and function in people taki

Review of donepezil, rivastigmine, galan
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population
โœ V. P. Prasher ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 2 views

## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of antiโ€dementia drugs. However, there is limited information available regarding the bioโ€medical aspects of the differing drugs; particularly relating to adults with intellectual disability